Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04409587 · ClinicalTrials.gov registry record · Phase 4
Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump
A Phase 4 study, sponsored by Mountain Diabetes and Endocrine Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
NCT04409587: Completed Phase 4 study, sponsored by Mountain Diabetes and Endocrine Center.
NCT04409587 is a Phase 4 study that has completed, run by Mountain Diabetes and Endocrine Center. The registered enrollment target is 59 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04409587, a Phase 4 study, has completed, sponsored by Mountain Diabetes and Endocrine Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
Study Summary
The purpose of this investigator-initiated trial is to compare the effect of a daily injection of insulin degludec vs. basal insulin delivery via Continuous Subcutaneous Insulin Infusion (CSII), both in combination with bolus insulin delivery via the patient's usual insulin pump with insulin aspart, on glycemic variability, overall blood glucose control and incidence of hypoglycemia, all assessed by continuous glucose monitor (CGM), as well as patient satisfaction, in patients with type 1 diabetes currently using CSII.
Primary Outcome
Percent time in euglycemia (BG 70 to 180 mg/dl) by CGM during the final 14 days of each treatment period during steady state (with basal insulin delivery as either one daily injection of insulin degludec or as insulin aspart via CSII)
Interventions
- DRUG Aspart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2018-04-12 |
| Est. Completion | 2020-11-01 |
| Phase | Phase 4 |
What the finished NCT04409587 record still lists
NCT04409587 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Aspart is the first listed.
NCT04409587 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04409587 about?
NCT04409587 is a clinical study titled "Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump". The purpose of this investigator-initiated trial is to compare the effect of a daily injection of insulin degludec vs. basal insulin delivery via Continuous Subcutaneous Insulin Infusion (CSII), both in combination with bolus insulin delivery via the patient's usual insulin pump with insulin aspart,...
What is the current status of trial NCT04409587?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2018-04-12. Estimated completion is 2020-11-01.
What interventions are being tested in trial NCT04409587?
The interventions under investigation include: Aspart (DRUG).
Who is sponsoring clinical trial NCT04409587?
This trial is sponsored by Mountain Diabetes and Endocrine Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04409587's enrollment target sits among peer trials
59 1202nd of 2000 higher than 796 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI